Disease Domain | Count |
---|---|
Nervous System Diseases | 6 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Chemical drugs | 1 |
Target |
Mechanism SIRT2 inhibitors |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TRPA1 inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TRPA1 inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date20 Aug 2024 |
Sponsor / Collaborator |
Start Date17 Jun 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
JZP-361 ( H1 receptor x MAGL ) | - | Preclinical |
KYP-2047 ( PREP ) | Memory Disorders More | Preclinical |
TRPA1 inhibitors-5(University of Eastern Finland) ( TRPA1 ) | Inflammation More | Preclinical |
TRPA1 inhibitors-12(University of Eastern Finland) ( TRPA1 ) | Pain More | Preclinical |
KPM-2 ( SIRT2 ) | Neoplasms More | Preclinical |